Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Hepa save search
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -17.36%
H: 16.86%
C: 2.46%
liver disease treatment pharmaceuticals study
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.05%
H: 29.77%
C: 1.34%
liver conference review pharmaceuticals trial phase 2
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
Published: 2023-09-19 (Crawled : 13:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.97%
H: 8.1%
C: 2.64%
liver cancer pharmaceuticals
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
Published: 2023-06-15 (Crawled : 21:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.69%
H: 0.82%
C: 0.26%
liver international pharmaceuticals
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
Published: 2023-06-15 (Crawled : 21:00) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.69%
H: 0.82%
C: 0.26%
liver international pharmaceuticals
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
Published: 2023-05-22 (Crawled : 11:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 47.63%
H: 0.0%
C: 0.0%
liver trial biomarkers nash
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-05-19 (Crawled : 20:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
| Email alert
Add to watchlist
liver conference review pharmaceuticals topline trial results phase 2
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
Published: 2023-03-30 (Crawled : 13:00) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.25%
H: 8.7%
C: 7.45%
liver disease pharmaceuticals
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Published: 2022-12-05 (Crawled : 14:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.13%
H: 6.63%
C: -0.88%
pharmaceuticals liver trial phase 2
Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
Published: 2022-11-02 (Crawled : 12:20) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.94%
H: 2.25%
C: -2.44%
meeting pharmaceuticals liver
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
Published: 2022-09-14 (Crawled : 12:20) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -2.99%
H: 8.25%
C: 2.92%
liver disease meeting presentation potential
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Published: 2022-09-12 (Crawled : 12:20) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.92%
H: 1.72%
C: -0.56%
liver trial phase 2
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
Published: 2022-06-15 (Crawled : 12:20) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.03%
H: 5.73%
C: 2.64%
liver international
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Published: 2022-01-26 (Crawled : 13:00) - hepionpharma.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.0%
H: 2.45%
C: -4.42%
als liver cancer
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Published: 2021-12-21 (Crawled : 13:00) - hepionpharma.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.83%
H: 7.38%
C: 0.82%
crv431 treatment fda als clearance application liver fda clearance cancer
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Published: 2021-11-16 (Crawled : 14:00) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.07%
H: 0.0%
C: 0.0%
cancer liver crv431 preclinical
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
Published: 2021-11-10 (Crawled : 13:00) - hepionpharma.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 3.11%
H: 0.67%
C: -2.01%
liver
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
Published: 2021-11-10 (Crawled : 13:00) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 3.11%
H: 0.67%
C: -2.01%
cancer research liver crv431
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
Published: 2020-12-02 (Crawled : 16:00) - biospace.com/
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -5.36%
disease liver potential crv431